Monoclonal antibodies and immunoconjugates / Anticorpos monoclonais e imunoconjugados

ABSTRACT

Chimeric and radiolabeled antibodies produce high objective remission rates in patients with B cell lymphomas. Response rates using chimeric anti-CD20 antibodies are highest in patients with indolent lymphomas, intermediate in patients with mantle cell and diffuse large cell lymphomas, and lowest in patients with small lymphocytic lymphomas. Patients with newly diagnosed lymphomas have the highest response rates to antibodies and radioimmunoconjugates, whereas relapsed and refractory patients have lower but still substantial response rates. Further studies will be necessary to determine the optimal setting for antibody therapies and to define potential interactions with chemotherapy and other antibody conjugates.

RESUMO

No relato é apresentado o histórico do emprego clínico dos anticorpos monoclonais no tratamento dos linfomas não-Hodgkin. Descreve-se o uso do anti-CD20, os resultados e perspectivas futuras com imunotoxinas, Iodo e o Ytrium. Na sequência, é descrita a perspectiva do emprego em Seattle, EUA, da radioimunoterapia mieloblativa seguida do suporte de células progenitoras.